Abstract:Xiao Liang Qiya Yang Wanchun Wang Tang Liu Jinyue Hu 1Department of Orthopaedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, People’s Republic of China; 2Chengnan Academy, Hunan First Normal University, Changsha, Hunan 410002, People’s Republic of China; 3Medical Research Center, Changsha Central Hospital, Changsha, Hunan 410004, People’s Republic of China Introduction: Cisplatin has been reported to elicit the DNA damage response (DDR) via activation of the ATR-Chk1 pathway, which in turn contributes to the induction of cisplatin resistance. Inhibition of ATR-Chk1 signaling reverses cisplatin resistance in some cancers. However, the influence of inhibiting ATR-Chk1 signaling on cisplatin resistance in chondrosarcoma cancer has not been reported. Materials and methods: We compared the expression levels of ATR kinases in human nasopharyngeal carcinoma, choriocarcinoma and chondrosarcoma cell lines. We inhibited ATR kinase function with VE-822, a selective ATR inhibitor, and suppressed ATR kinase expression with shRNA. Western blotting, the CCK-8 assay, cell cycle distribution assay and apoptosis analysis were used to study the influence of inhibiting ATR-Chk1 signaling on reversing cisplatin resistance in chondrosarcoma cell lines. Results: We found that chondrosarcoma cells expressed very low basal levels of phosphorylated ATR, but cisplatin treatment induced the activation of ATR-Chk1 signaling in a doseand time-dependent manner, suggesting the induction of DDR. As expected, ATR inhibition with VE-822 reversed cisplatin-induced DDR and enhanced cisplatin-induced activation of H2AX, which is an important marker of DNA damage. Meanwhile, ATR inhibition by RNA interference also reversed DDR and promoted DNA damage. Furthermore, both pharmacological and molecular inhibition of ATR accelerated cisplatin-induced inhibition of cell proliferation and cell death. Conclusion: Our results suggested that inhibiting ATR activation promoted cisplatininduced cell death via reversion of DDR, and VE-822 may be a valuable strategy for the prevention of cisplatin resistance in chondrosarcoma.

Knockdown of REV3 Synergizes with ATR Inhibition to Promote Apoptosis Induced by Cisplatin in Lung Cancer Cells

REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells

BEZ235 reduction of cisplatin resistance on wild-type EGFR non-small cell lung cancer cells

Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells

Co-inhibition of Pol Θ and HR Genes Efficiently Synergize with Cisplatin to Suppress Cisplatin-Resistant Lung Cancer Cells Survival

REV3L Confers Chemoresistance to Cisplatin in Human Gliomas: the Potential of Its RNAi for Synergistic Therapy

TR4 Nuclear Receptor Enhances the Cisplatin Chemo-Sensitivity Via Altering the ATF3 Expression to Better Suppress HCC Cell Growth

REV3L, a Promising Target in Regulating the Chemosensitivity of Cervical Cancer Cells.

Simultaneous Targeting of ATM and Mcl-1 Increases Cisplatin Sensitivity of Cisplatin-Resistant Non-Small Cell Lung Cancer

The Identification of the ATR Inhibitor VE-822 As a Therapeutic Strategy for Enhancing Cisplatin Chemosensitivity in Esophageal Squamous Cell Carcinoma

Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse

MicroRNA‑29a Enhances Cisplatin Sensitivity in Non‑small Cell Lung Cancer Through the Regulation of REV3L.

ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe

XRCC1 Arg399Gln and Arg194Trp Polymorphisms Regulate XRCC1 Expression and Chemoresistance of Non-Small Cell Lung Cancer Cells

Ott_a_211560 6083..6092

The synergistic effect of resveratrol in combination with cisplatin on apoptosis via modulating autophagy in A549 cells.

The Reversing and Molecular Mechanisms of Mir-503 on the Drug-resistance to Cisplatin in A549/DDP Cells

Proteomics reveals a therapeutic vulnerability via the combined blockade of APE1 and autophagy in lung cancer A549 cells

Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR)

Synergistic Lethality Between Auranofin-Induced Oxidative DNA Damage and ATR Inhibition in Cancer Cells

Enhanced Cisplatin Cytotoxicity by RNA Interfering the Excision Repair Cross-complementing Gene 1 in Lung Cancer Cell A549/DDP